Literature DB >> 12633905

Lysosomal dysfunction in muscle with special reference to glycogen storage disease type II.

Reinout P Hesselink1, Anton J M Wagenmakers, Maarten R Drost, Ger J Van der Vusse.   

Abstract

The importance of proper lysosomal activity in cell and tissue homeostasis is underlined by "experiments of nature", i.e. genetic defects in one of the at least 40 lysosomal enzymes/proteins present in the human cell. The complete lack of 1-4 alpha-glucosidase (glycogen storage disease type II (GSD II) or Pompe disease) is life-threatening. Patients suffering from GSD II commonly die before the age of 2 years because of cardiorespiratory insufficiency. Striated muscle cells appear to be particularly vulnerable in GSD II. The high cytoplasmic glycogen content in muscle cells most likely gives rise to a high rate of glycogen engulfment by the lysosomes. The polysaccharides become subsequently trapped in these organelles when 1-4 alpha-glucosidase activity is absent. During the course of the disease, muscle wasting occurs. It is hypothesised that the gradual loss of muscle mass is caused by a combination of disuse atrophy and lipofuscine-mediated apoptosis of myocytes. Moreover, we hypothesise that in the remaining skeletal muscle cells, longitudinal transmission of force is hampered by swollen lysosomes, clustering of non-contractile material and focal regions with degraded contractile proteins, which results in muscle weakness.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12633905     DOI: 10.1016/s0925-4439(02)00229-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  13 in total

1.  A modified PAS stain combined with immunofluorescence for quantitative analyses of glycogen in muscle sections.

Authors:  Gert Schaart; Reinout P Hesselink; Hans A Keizer; Gerrit van Kranenburg; Maarten R Drost; Matthijs K C Hesselink
Journal:  Histochem Cell Biol       Date:  2004-08-03       Impact factor: 4.304

Review 2.  Pros and cons of different ways to address dysfunctional autophagy in Pompe disease.

Authors:  Jeong-A Lim; Naresh Kumar Meena; Nina Raben
Journal:  Ann Transl Med       Date:  2019-07

3.  Therapeutic Benefit of Autophagy Modulation in Pompe Disease.

Authors:  Jeong-A Lim; Baodong Sun; Rosa Puertollano; Nina Raben
Journal:  Mol Ther       Date:  2018-05-03       Impact factor: 11.454

Review 4.  Acid alpha-glucosidase deficiency (Pompe disease).

Authors:  Tokiko Fukuda; Ashley Roberts; Paul H Plotz; Nina Raben
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

5.  Muscle fiber-type distribution, fiber-type-specific damage, and the Pompe disease phenotype.

Authors:  L E M van den Berg; M R Drost; G Schaart; J de Laat; P A van Doorn; A T van der Ploeg; A J J Reuser
Journal:  J Inherit Metab Dis       Date:  2012-10-11       Impact factor: 4.982

6.  A study of glycogen storage disease with 99Tcm-MIBI gated myocardial perfusion imaging.

Authors:  L G Wei; J Q Gao; X M Liu; J M Huang; X Z Li
Journal:  Ir J Med Sci       Date:  2013-04-25       Impact factor: 1.568

7.  Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease.

Authors:  Nina Raben; Victoria Hill; Lauren Shea; Shoichi Takikita; Rebecca Baum; Noboru Mizushima; Evelyn Ralston; Paul Plotz
Journal:  Hum Mol Genet       Date:  2008-09-09       Impact factor: 6.150

Review 8.  Epigenetic drugs in the treatment of skeletal muscle atrophy.

Authors:  Valentina Guasconi; Pier Lorenzo Puri
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2008-05       Impact factor: 4.294

Review 9.  Pompe disease: from pathophysiology to therapy and back again.

Authors:  Jeong-A Lim; Lishu Li; Nina Raben
Journal:  Front Aging Neurosci       Date:  2014-07-23       Impact factor: 5.750

Review 10.  A lysosome-centered view of nutrient homeostasis.

Authors:  Vinod K Mony; Shawna Benjamin; Eyleen J O'Rourke
Journal:  Autophagy       Date:  2016       Impact factor: 16.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.